Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.40 |
| ▸ | MGAM | O43451 | 2/20 | 0.39 |
| ▸ | SI | P14410 | 2/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.39 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29541717 | 1.00 | EPHX2 (0.43) | EPHX2GAAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL9681107 | 0.84 | EPHX2 (0.47) | EPHX2GAAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4053851 | 0.77 | EPHX2 (0.67) | EPHX2GAAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL6817772 | 0.75 | CYP1A2 (0.47) | EPHX2GAAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL29541546 | 0.75 | CYP1A2 (0.47) | EPHX2GAAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL29541410 | 0.75 | NOTUM (0.41) | EPHX2GAAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL29542034 | 0.73 | EPHX2 (0.44) | EPHX2GAAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL9135463 | 0.72 | ALDH1A1 (0.52) | ALDH1A1KDM4EKMO | |
| SCHEMBL3691118 | 0.72 | SLC9A1 (0.36) | GAAALDH1A1PDE4BMGAMSI | |
| SCHEMBL8375031 | 0.72 | ACKR3 (0.47) | GAAALDH1A1KDM4EPDE4BMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0486782-A1 | Improved process for the synthesis of alpha-((dialkylamino)substituted-methylene)-beta-oxo-(substituted) propanenitriles | AMERICAN CYANAMID COMPANY (US) | 1992-05-27 | — | — | EP | claimed |
| US-5103015-A | 5-(substituted)isoxazole compounds | AMERICAN CYANAMID COMPANY (US) | 1992-04-07 | — | — | US | claimed |
| US-20250325534-A1 | MICROBIOCIDAL TETRAHYDROISOQUINOLINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2025-10-23 | — | — | US | disclosed |
| US-20240343717-A1 | MICROBIOCIDAL PYRAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-10-17 | — | — | US | disclosed |
| CN-109068631-A | Solvent-free formulations of low melting active ingredients | 拜耳作物科学股份公司 | 2018-12-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325534-A1 | MICROBIOCIDAL TETRAHYDROISOQUINOLINE DERIVATIVES | IFNG, NOX1, CYP1A1 | EPHX2 1264/4885GAA 1396/4885ALDH1A1 939/4885 |
| US-20240343717-A1 | MICROBIOCIDAL PYRAZOLE DERIVATIVES | NOX1, CASP1, CYP51A1 | EPHX2 2219/4885GAA 1659/4885ALDH1A1 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.